Claerhout H, et al. - Researchers reviewed clinicopathological data from patients with de novo and with secondary myeloid sarcoma in order to provide significant information to facilitate its diagnosis. Presentation of most de novo cases was either isolated myeloid sarcoma or myeloid sarcoma with concurrent acute myeloid leukemia. Most secondary cases presented after acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome. Lesions were often found to be localized at skin and lymph nodes. In de novo cases and in secondary cases, genetic aberrations frequently involved core-binding factor rearrangements and a complex karyotype, respectively. De novo cases were mostly treated with induction chemotherapy followed by consolidation chemotherapy or allogeneic stem cell transplantation and secondary cases with radiotherapy.